NEW YORK, NY / ACCESSWIRE / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -81.35%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

RBC Capital Mkts has recently reduced Neumora Therapeutics Inc (NMRA) stock to Sector Perform rating, as announced on January 2, 2025, according to Finviz. Earlier, on November 5, 2024, JP Morgan had ...

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies.

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 5,936 call options on the stock. This represents an increase of 45% ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 study for major depressive disorder, causing an 80% stock drop yesterday.

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.” ...

Neumora Therapeutics, Inc., a Delaware-based company listed on the Nasdaq Global Select Market under the ticker symbol “NMRA,” recently disclosed its latest developments in a Form 8-K filing ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials Neumora Therapeutics Inc.'s stock tumbled 81% Thursday after the clinical-stage biotech said a ...